INTRODUCTION {#s1}
============

Africa is host to \> 18% of the world's population and 3% of the global pharmaceutical market, but it attracts \< 1% of registered clinical trials.^[@B1]^ Despite the advantage Africa offers with its unique and diverse genetic pool and ease of recruiting trial participants in pathologies like sickle cell anemia, prostate cancer, and some infectious diseases, Africa is still disproportionately poorly represented in clinical research. In this article, we will examine reasons for this. We argue that collaboration among stakeholders in the clinical trial ecosystem can improve the attractiveness of Africa as a clinical trial destination for sponsors. Regulatory agencies, researchers/clinicians, research sites, and sponsors can play key roles in improving the ease of conducting trials in Africa.

CONTEXT
-------

**Key Objective**This article highlights how partnerships and collaborations among stakeholders can help attract clinical trials to Africa based on local experience and literature review.**Knowledge Generated**These partnerships must involve regulatory agencies, clinicians, researchers, sites, patients, and sponsors as identified stakeholders in the clinical trial ecosystem. Development of certification and continuous training for players involved is essential to support conduct of more clinical trials in Africa.**Relevance**One solution to enable the standardization and uniformity necessary for the conduct of clinical trials in Africa may be a single regulatory jurisdiction for the continent, a framework for the achievement of which is proposed in this article.

54 COUNTRIES, 54 MARKETS, 54 REGULATORY JURISDICTIONS {#s2}
=====================================================

Each of Africa's 54 countries represents a regulatory jurisdiction for clinical trials and market for health care products. Each of these countries competes for clinical trials with India and China, each of which has roughly the population as Africa but offers sponsors one regulatory jurisdiction and, in the case of China, a much bigger market. Sponsors are likely to find it easier to deal with a single regulatory agency, as in each of these two countries, than with the 54 that Africa presents.

Also complicating the bureaucratic challenge of conducting trials in Africa is the fact that national regulatory agencies are at different maturity levels.^[@B2]^ Therefore, the case for partnership and collaboration to support clinical trials in Africa is a compelling one. Collaboration among Africa's national regulatory agencies (NRAs) for medicines could improve competitiveness for clinical trials, although planning and implementation of this remain challenging.

COLLABORATION AMONG RESEARCHERS IN AFRICA {#s3}
=========================================

Aided by advances in information-sharing technologies and social media platforms, such as ResearchGate,^[@B3]^ collaborative research is already in practice and is evidenced by the rapid growth in the number of authors in a publication. Health research assumed collectively by more than one researcher/clinician within the same department, or across academic departments in an institution or in different academic institutions or industries, has also become more common across countries. It provides opportunity for collaborators to share expertise and resources and expand their skills and worldviews on health issues. It may yield improved and unique data that can be used to design specific drugs and targeted medical interventions.

Successful collaboration is built on trust, understanding, and selflessness. It entails putting the interests of the team and participants first. It provides an opportunity for putting expertise and resources together to advance medical knowledge for appropriate intervention.

Global collaborative health research is essential to addressing complex diseases, such as cancer, a growing problem in Africa. It requires multidisciplinary expertise. Collaboration among social workers, physicians, nurses, scientists, and industries has proven to be essential in conducting successful clinical research. This collaboration benefits not only the patients and the science behind treatment, but also individual researchers mentoring younger ones to develop scholarly attributes. Cross-cultural collaboration promotes healthy interaction among scientists from different countries, ensuring scientists and oncologists gain a broader worldview of the burden of cancer, social interplay, and management. It goes without saying that ethically based collaboration can yield better scientific data, increase the capacity for research, improve funding, empower partners, expose collaborators from different countries to different cancer biologies, and contribute to the personal and professional development of all involved.

Despite its many benefits, collaborative research may have setbacks. The heterogeneity of the sociocultural backgrounds of scientists involved, resources (time and money) contributed, professional reputations of researchers, and attributions of credit (authorship) may be sources of tension.^[@B4]^ A culturally unfit and ill-conceived collaboration can destroy trust and breed hostility toward future collaborations.

COLLABORATION AMONG SITES TO HARMONIZE TREATMENT GUIDELINES AND BOOST EFFICIENCY {#s4}
================================================================================

Various models of collaborative partnerships between sites within a country or region or between regions have their own merits and pitfalls. Advantages include addressing of common areas of interest, transfer of knowledge and skills, local mentorship of young investigators, ease of recruitment of trial participants, provision of a wider range of clinical judgments, and provision of local evidence for the subsequent generalization of trial findings.

For many African clinical trials, the scenario is usually that of a single or multiple sites collaborating with an international site. Collaboration among African sites seems to be rare. Many reasons have been postulated for this, including lack of funding and limited research capacity. High-income countries fill the gap by conceptualizing, coordinating, and funding African studies, and the resultant effect at times is the promotion of trials that are not of critical importance to Africa's health care problems.^[@B5]-[@B7]^

Most African countries have similar challenges in cancer management, and there is a dearth of local evidence-based solutions and approaches. More collaborations among African sites should be encouraged to facilitate the development of local treatment guidelines and comprehensive national cancer control programs. Collaboration among sites provides a platform for plugging existing gaps in an efficient and timesaving manner and expediting the generation of extensive data. This was successfully demonstrated in a study performed in one African country among 12 sites in one region. The collected data included trends in HIV prevalence, HIV incidence, HIV-associated and all-cause mortality, sexual risk behaviors, and health-seeking behaviors. The investigators were able to measure the effects of prevention and treatment programs on the HIV epidemic and generalize them to the whole country.^[@B8]^ In another publication, a review of collaboration between HIV care centers and cancer centers was carried out. The findings demonstrated the merits of integrating cancer research with established HIV programs to obtain timely data about the incidence and burden of cancer in HIV-infected persons in Africa.^[@B9]^

Collaboration among sites also generates problem-solving solutions through standardization and adherence to case definitions, clinical procedures, laboratory methods, and specimen collection techniques.^[@B10]^ Broader collaboration corrects for the differences in practice norms that are inevitable across countries and continents. Addressing and defining the standard of care at various trial sites are important. Study data are credible only if the quality of collection and processing of data are standardized across sites, especially in resource-constrained situations. Challenges such as the lack of qualified personnel and experience in designing software tools and complex databases are common in Africa. These challenges can be effectively resolved if identified earlier on in the design of studies.^[@B11],[@B12]^ The recognition of potential harm in sharing data among sites has been explored. One study explored the possibility of the use of genomic data in ways that could cause perceived harm to ethnic groups involved in studies. The potential for abuse may arise where there is sharing of genomic data outside the original group collaborating. Trust is important for such collaborations to thrive, and safeguarding against such misuse is important.^[@B13]^

Recognition and integration of work culture are important for successful collaboration across sites, especially in Africa, where diverse ethnicities make regional as well as international collaborations intriguing.^[@B14]^ To this effect, international clinical electives have been shown to be effective in preparing young potential investigators to receive cross-cultural educational and gain research skills to equip them for future collaborative work.^[@B15]^

COLLABORATING TO ASSURE QUALITY OF OUTCOMES ACROSS BORDERS {#s5}
==========================================================

The paucity of clinical trials in Africa compared with other low- and middle-income countries is also blamed on the lack of stringent quality assurance measures and training to execute the processes necessary to maintain quality of outcomes. Compared with high-income countries, many institutions in Africa do not have training modules in clinical trials for frontline health practitioners, resulting in the major activities of the required processes being outsourced to international partners.^[@B16]^ Many trials involve several interlacing disciplines and therefore require that each aspect has the ability to contribute efficiently and appropriately. Best practices to improve clinical trials in Africa involve ensuring standardization of processes, starting from capacity building and continuing through liaison with partners conducting high-quality clinical trials and thereby improving quality. The best way to ensure standardization and uniformity across the continent is to have processes verified by universally acclaimed certification. This may involve several exchange visits, human resource training, and equipment upgrades. Principal investigators or key players must be encouraged to obtain clinical research associate certification, which will include a course on good clinical practice offered by an accredited institution, usually involving an examination. Institutions must be certified to ensure provision and maintenance of required infrastructure, and this should be an initial focus of engagement with international collaboration to develop capacity. Formation of regional consortiums must be encouraged to improve quality, scale cultural barriers, and identify regional certification opportunities.

Currently, mandatory courses for certification are fundamentals of clinical trials, human participant safety, and regulatory requirements for medical devices and pharmaceutical products. However, bioethics, health law, and data management are parts of good clinical practice and should also be mandatory, because they are critical to initiation, enrollment, reporting, and outcomes.^[@B17],[@B18]^ A mandatory requirement to register clinical trials in international, national, or regional platforms will also increase proficiency and transparency and serves as a form of certification to improve standards of conducting clinical trials. Indeed, many will strive for listing in regional or international registries with international accreditation. This module was instituted in Italy for phase I trials and resulted in increased standards and increased requests to obtain accreditation to conduct clinical trials in this category.^[@B19]^ WHO has developed guidelines for clinical trials registries, which could be embraced as a template by sub-Saharan African institutions.^[@B20],[@B21]^ A retrospective study from the United States demonstrated improved standards after accredited good practice certification in four randomized trials.^[@B22]^

PAYERS, CONTRACT RESEARCH ORGANIZATIONS, AND PHARMACEUTICAL COMPANIES {#s6}
=====================================================================

Unlike many high-income countries, private insurance does not play a dominant role in health care in Africa. Except for South Africa, the main payer is the government. It is prudent to recognize the emerging role of payers in the trajectory of the clinical trials landscape, because they, as with other stakeholders, will enable end-user access to these new interventions. Early collaboration will ensure minimal waste of resources, prioritize needs, formulate research questions, and enhance cost effectiveness of new innovations. This will help reduce financial losses and health care burden as a result of adverse effects of new interventions.

In recent years, there has been an increase in the number of biopharmaceutical companies using the services of contract research organizations (CROs) and other clinical trial service providers for the delivery of their research and development operations. In a research and market report published in June 2015, it was mentioned that by 2020, an estimated 72% of all clinical trials will be outsourced to CROs^[@B23]^; this is approximately three fourths of clinical trials.

A CRO provides research and clinical trial support services to the pharmaceutical, biotechnology, and medical device industries as well as to academic institutions, foundations, government organizations, and hospitals on a contract basis. An individual, company, institution, business, organization, or group of organizations that contracts with a CRO is called a sponsor.

Major pharmaceutical companies have a presence in Africa and are in partnerships with local businesses for support in navigating the diverse and heterogeneous market of \> 50 countries. The pharmaceutical industry is increasingly looking toward emerging markets, including Africa, for drug development and basic research. It is estimated that the pharmaceutical industry is expected to invest \$45 billion on the continent by 2020. Countries like Egypt and South Africa are home to 75% of the 8,897 clinical trials in Africa as a result of their comparative economic strength, followed by Tunisia, Kenya, Uganda, Tanzania, Zambia, and Burkina Faso, documenting at least 200 trials in the year 2019.^[@B24]^ These countries are striving for health improvements through strategic investments and promotion and facilitation of clinical research.

Pharmaceutical companies will often partner with technology organizations and CROs to set up and run their clinical trials. The CROs have access to local knowledge; they work with investigators and local clinical research teams in the identification and recruitment of patients, collection and analysis of patient data, and assessment of patient safety as regards adverse effects.^[@B25]^ There are global CROs with offices in Africa, and there are also locally established CROs. These organizations often work together in the delivery of clinical trial services.

CROs fall into different types. Preclinical CROs, which perform testing of drugs or medical devices before the compounds or devices go on to the human or clinical phase to ensure safety and effectiveness. Clinical CROs specialize in patient recruitment, site selection, monitoring, medical writing, regulatory preparation of applications to ethics committees and regulatory authorities, data management, and other clinical trial services.

CROs understand the local climate best suited for business with related economic outcomes for their investors, owners, and shareholders. For a successful CRO-sponsor collaboration, it is necessary for the sponsor to choose a CRO that will be an effective partner. This collaboration can be both rewarding and rich if it is well established. For the sponsor, outsourcing clinical trials via CROs has the potential to reduce costs and provide access to local knowledge and local expertize (country experts) in various geographic markets, thereby giving sponsor a global reach.

The following are keys to a successful CRO-sponsor collaboration: defining common goals up front, engaging in shared decision making, and establishing clear communication and practical project management plans as well as secure cloud platforms to be used for data sharing by the CRO and sponsor; defining what information is to be communicated during the study, the frequency of communications, and which issues require escalation^[@B26]^; and establishing the key performance indicators and how performance will be measured against set goals. In addition, an effective two-way communication process should be in place. These practices will create an atmosphere for positive collaboration that is beneficial to the partners and will help to strengthen the CRO-sponsor partnership.

The African Union is supporting the creation of an African medicines agency to coordinate the regulation of medicines, including clinical trials all over Africa. In 2006, the African Vaccine Regulatory Forum (AVAREF), a network of NRAs and ethics committees, was established by WHO to strengthen regulation, initially of vaccines, but lately, the platform has been extended to other medicines, and a joint review platform has been developed that sponsors can leverage to have their applications reviewed simultaneously by AVAREF member countries. It is a platform that has been used to review some clinical trial applications, especially during emergencies, and working documents and guidelines have been developed for harmonization within the continent to enable sponsors to develop a single application package (in case of multinational clinical trials) for review.

In conclusion, we believe that collaboration among clinicians, researchers, sites, and regulatory agencies is essential to making Africa an attractive destination for clinical trials. This, alongside quality certification of personnel, sites, and process, will win the trust of sponsors and CROs. All these moving parts must run on a framework that will make research seamless and outcomes trusted.

The first recommendation is for Africa to present just one regulatory jurisdiction to sponsors. The feasibility and applicability of this must be assessed with the diversity of practice within the continent of Africa in mind. Good clinical practice guidelines, training modules in clinical trials, and site checklists must be coordinated, with mutual recognition of inspections by different NRAs to reduce costs and bureaucratic burdens. To ensure standardization and uniformity across the continent, processes must be verified by universally acclaimed certification.
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